A.P. Pharma Says Begins Search for CEO Successor
REDWOOD CITY, Calif. -- A.P. Pharma, a specialty pharmaceuticals company, today announced that its board of directors has initiated an executive succession program designed to recruit a well-qualified successor for Gregory Turnbull, the Companyâ€™s current President and Chief Executive Officer. Mr. Turnbull, a long-time director of the Company, assumed the CEO position in October 2006 when Michael Oâ€™Connell, the incumbent at that time, departed on medical leave. Mr. Turnbull plans to continue to serve as A.P. Pharmaâ€™s CEO until his successor is successfully engaged, at which time he will remain on the board and also continue to be a member of its recently formed executive committee.
The A.P. Pharma board has retained the services of Levin & Company, an executive search firm specializing in the life sciences field, to assist in the CEO recruitment. Christos Richards, President of Levin & Company, is leading the engagement.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Companyâ€™s primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomerâ„¢. Initial target areas of application for the Companyâ€™s drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications. For further information visit the Companyâ€™s web site at www.appharma.com.
Contact: Company Contacts: A.P. Pharma, Inc. Gregory Turnbull President and Chief Executive Officer 650-366-2626 or Michael Oâ€™Connell Chief Financial Officer and Chief Operating Officer 650-366-2626 or Investor Relations Contacts: Lippert/Heilshorn & Associates Don Markley, 310-691-7100 [email protected]